Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess the Safety, Tolerability, PD and PK of RLS-0071 in Healthy Adult Subjects After Challenge With Inhaled Lipopolysaccharide (LPS)

Next Previous
Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess the Safety, Tolerability, PD and PK of RLS-0071 in Healthy Adult Subjects After Challenge With Inhaled Lipopolysaccharide (LPS)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegtarazimod (Primary) ; Lipopolysaccharide
  • Indications Acute lung injury; Asthma; Brain hypoxia-ischaemia; Brain injuries
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors ReAlta Life Sciences

Most Recent Events

  • 19 May 2025 According to a ReAlta Life Sciences media release, a poster presentation featuring new analysis of clinical data using samples from this trial, and AE-COPD program will be presented at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025 in San Francisco.
  • 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society
  • 05 Sep 2023 According to a ReAlta Life Sciences media release, additional clinical data from this trial will be presented at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023, data will be presented by the Prof. Dr. Jens M. Hohlfeld.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top